PubMed Health⌕ Search

Biomedical subjects

D W Moran

Publications and source records attributed to D W Moran.

23 records · Page 2Linked to original sources

HMOs, competition, and the politics of minimum benefits.

Attempts to inject "competition" into the market for health-care financing have been inextricably linked to the fate of the HMO movement. But the track record of HMOs to date offers no compelling evidence that all other types of competitors should be barred from the race, and a new Congress is likely to be more critical of optimal "second-best" solutions than were its recent predecessors. An accommodation to some constraints may be the best public protection against the "minimum benefit" politics of special interests.

Commerce↗

Federal regulation of managed care: an impulse in search of a theory?

Although there is growing demand for regulation of the managed care industry, regulatory proponents have yet to articulate a clear theory of regulation. Most observers acknowledge consumer information problems that regulation could address, but there is no consensus regarding regulation of the broader public concern about restrictive medical-necessity determinations by health plans. Concerns about these issues--which fall within the gray areas of divergent clinical opinion--may be difficult or impossible to address by explicit regulation. If policymakers forbear on regulation of medical-necessity determinations, private market innovation may ultimately remedy this problem.

Consumer Advocacy↗

Health information policy: on preparing for the next war.

As policymakers demand more and better information about health care, the private health information technology industry is investing heavily to produce the "paperless clinical enterprise" of the future: the infrastructure that will be required to satisfy those demands. Developments on a number of policy fronts, however--from medical privacy legislation to clinical software regulation to "telehealth"--suggest the need for a conscious health information policy that will inform the debate in each niche area with a larger sense of whether public policy will promote or retard private innovation in this area. Given the stakes involved, and the immediacy of the issues, leadership in this direction is badly needed.

Confidentiality↗

Prescription drugs and managed care: can 'free-market détente' hold?

The rapid rise in pharmaceutical benefits costs, often cited as a major contributor to the resurgence in health care cost growth, is beginning to strain the relationship between the pharmaceutical and the managed care industries in the United States. In interviews conducted in 1999, executives from both industries maintained a continued preference for a market-based resolution of these tensions. There is evidence, however, that this private-sector détente may give way in the face of the rising business and political pressures that both industries face. Active leadership will be required to prevent deterioration of the prevailing political climate toward economic controls.

Administrative Personnel↗